Each new medication or advance in medical technology represents years of very expensive research. After safety and effectiveness have been demonstrated in the lab and in animals, a product or technique must be evaluated in a large group of human subjects before approval by the Food and Drug Administration. Clinical trials often take years to complete and may involve several medical centers and teams of investigators.
The Tufts Center for Drug Development estimated last year that each new prescription medication cost on average $2.6 billion and took more than 10 years to develop and gain approval. Costs had increased almost 150 percent over the preceding decade, the center said.
Even after a new drug or technology is approved, its affordability must be addressed. Health-care dollars are not limitless. Government policymakers and insurance companies must determine if coverage for a medical advance is worth the cost.
Since the late 1960s, effectiveness and affordability of therapy have been expressed in terms of “quality adjusted life years,” or QALY, the term used inside the industry. The mathematics behind this computation are complex. Both quality and quantity of life are measured after a medical intervention for a suspected or confirmed diagnosis. A year of perfect health following a procedure is considered one QALY, while a year of bedridden life might be ranked as one-half QALY.
For decades, a cutoff of $50,000 per QALY has been used to assess the affordability of a test or treatment. Drugs or procedures costing more than that were unlikely to be approved for coverage by insurance companies or governmental programs. But this ceiling has been repeatedly challenged in recent years.
